Hennion & Walsh Asset Management’s Autolus Therapeutics AUTL Stock Holding History

Hennion & Walsh Asset Management’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$722K	Buy	451,403 +11,197	+3%	+$17.6K	0.02%	657
2026 Q1	$607K	Sell	440,206 -13,622	-3%	-$20.7K	0.02%	659
2025 Q4	$903K	Buy	453,828 +33,247	+8%	+$51.1K	0.03%	545
2025 Q3	$686K	Sell	420,581 -7,737	-2%	-$15.1K	0.02%	618
2025 Q2	$977K	Buy	428,318 +42,317	+11%	+$70K	0.04%	498
2025 Q1	$598K	Buy	386,001 +126,021	+48%	+$256K	0.03%	590
2024 Q4	$611K	Buy	+259,980	New	+$879K	0.03%	577

Other funds holding AUTL

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Hennion & Walsh Asset Management's AUTL Position: Q2 2026 in Review

Hennion & Walsh Asset Management increased its Autolus Therapeutics (AUTL) stake by 2.5% in Q2 2026, buying an estimated $17.6K and bringing the position to 451,403 shares worth $722K. The position accounts for 0.02% of the portfolio, ranked #657.

Hennion & Walsh Asset Management first reported a position in AUTL in Q4 2024 and has held it in 7 quarters since. The position peaked at $977K in Q2 2025. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

Hennion & Walsh Asset Management held 451,403 shares of Autolus Therapeutics worth $722K as of Q2 2026.
Hennion & Walsh Asset Management bought 11,197 Autolus Therapeutics shares in Q2 2026, an estimated $17.6K.
Autolus Therapeutics made up 0.02% of Hennion & Walsh Asset Management's portfolio in Q2 2026, its #657 holding.
Hennion & Walsh Asset Management first reported a position in Autolus Therapeutics in Q4 2024 and has held it in 7 quarters since.
Hennion & Walsh Asset Management's Autolus Therapeutics position peaked at $977K in Q2 2025.
84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.